What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 1).

What question did this study set out to answer?

This research aims to explore the thrombopoietic effects of the ribosome biogenesis inhibitor CX-5461.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase I trial shows CX-5461 improves platelet count in haematological malignancy, suggesting new thrombopoietic therapy.

This research aims to explore the thrombopoietic effects of the ribosome biogenesis inhibitor CX-5461.
Conducted a phase I trial with patients having haematological malignancy.
Administered CX-5461 to C57BL/6 mice to evaluate megakaryopoiesis effects.
Analyzed bone marrow for megakaryocyte expansion and progenitor cell differentiation.
56% of patients experienced up to a 34% increase in platelet count after treatment.
CX-5461 induced rapid and sustained 1.7-fold increase in platelet numbers in mice.
Bone marrow analysis revealed a significant increase in megakaryocytes and MK-biased progenitor cells.

Ali et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark